Amlodipine/benazepril detailed information: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Amlodipine/benazepril detailed information": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 23: | Line 23: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Amlodipine/benazepril''', marketed in the U.S. as '''Lotrel''' by [[Novartis]] and manufactured as a [[generic drug]] by [[Teva Pharmaceutical Industries|Teva]], is an [[antihypertensive]] medication which combines a [[calcium channel blocker]] ([[amlodipine]] besylate) with an [[angiotensin converting enzyme inhibitor]] ([[benazepril]]). This combination agent, and other analogs, is prescribed when either agent alone is not sufficient to bring a person's blood pressure down to target range. As a combination agent, Lotrel shares the [[adverse drug reaction|adverse reaction]] profile of both of its individual parts. | '''Amlodipine/benazepril''', marketed in the U.S. as '''Lotrel''' by [[Novartis]] and manufactured as a [[generic drug]] by [[Teva Pharmaceutical Industries|Teva]], is an [[antihypertensive]] medication which combines a [[calcium channel blocker]] ([[amlodipine]] besylate) with an [[angiotensin converting enzyme inhibitor]] ([[benazepril]]). This combination agent, and other analogs, is prescribed when either agent alone is not sufficient to bring a person's blood pressure down to target range. As a combination agent, Lotrel shares the [[adverse drug reaction|adverse reaction]] profile of both of its individual parts. | ||
| Line 37: | Line 37: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 22:05, 8 August 2012
| File:Amlodipine.svg | |
| File:Benazepril.svg | |
| Combination of | |
|---|---|
| Amlodipine | Calcium channel blocker |
| Benazepril | ACE inhibitor |
| [[{{{component3}}}]] | ? Class |
| [[{{{component4}}}]] | ? Class |
| [[{{{component5}}}]] | ? Class |
| Clinical data | |
| Pregnancy category |
|
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Amlodipine/benazepril, marketed in the U.S. as Lotrel by Novartis and manufactured as a generic drug by Teva, is an antihypertensive medication which combines a calcium channel blocker (amlodipine besylate) with an angiotensin converting enzyme inhibitor (benazepril). This combination agent, and other analogs, is prescribed when either agent alone is not sufficient to bring a person's blood pressure down to target range. As a combination agent, Lotrel shares the adverse reaction profile of both of its individual parts.
External links
Categories:
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Calcium channel blockers
- ACE inhibitors